Pharmatest Services

Executive Summary

Pharmatest Services is a Finland-based preclinical contract research organization (CRO) founded in 2011, specializing in oncology and skeletal disease models. The company offers a full-service suite including in vitro assays, in vivo efficacy models, and ex vivo bone analysis, with particular expertise in bone metastasis and targeted radionuclide therapy. By providing clinically predictive preclinical models, Pharmatest aims to improve drug development success rates for its clients in the pharmaceutical and biotechnology sectors. Its niche focus on skeletal diseases and radionuclide therapy differentiates it from generalist CROs, positioning it as a valuable partner for companies developing therapies in these areas. The company operates from Turku, Finland, and is privately held with no disclosed financials or valuation. Pharmatest Services has established a reputation for high-quality preclinical services, leveraging its deep domain knowledge to support drug developers from early discovery through IND-enabling studies. While the company has not publicly announced major partnerships or funding rounds, its specialized capabilities are increasingly relevant as the industry invests in radiopharmaceuticals and bone-targeted therapies. With the global CRO market growing and demand for niche models rising, Pharmatest is well-positioned to capture a share of this specialized segment. The company's ability to maintain client confidentiality and deliver reproducible data will be key to its long-term growth and potential strategic transactions.

Upcoming Catalysts (preview)

• Q4 2026Major pharma partnership for radionuclide therapy models50% success
• Q2 2026Expansion of service offerings into immuno-oncology bone models70% success
• TBDAcquisition by a large CRO seeking specialized oncology capabilities30% success